Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

NCRI 2021 | FOCUS4-C: Adavosertib in metastatic colorectal cancer

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, discusses the results of the FOCUS4-C trial (EudraCT Number: 2012-005111-12), which assessed the WEE1 inhibitor adavosertib in patients with newly diagnosed TP53- and RAS-mutant metastatic colorectal cancer. Patients initially received 16 weeks of chemotherapy and then received adavosertib or active monitoring. The primary endpoint of progression-free survival (PFS) was met in the adavosertib arm, and adavosertib particularly benefited patients with left-sided primary tumors or KRAS exon 12/13 mutations. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.

Disclosures

Dr Seligmann has received honoraria/travel/consultancy fees from Servier, Merck Serono, Pierre Fabre, Roche Diagnostics, BMS, and GI Connect.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.